Correspondence 0001654954-23-015475 from Dermata Therapeutics, Inc. (DRMA)

Dermata Therapeutics, Inc.
Date: Dec. 13, 2023 · CIK: 0001853816 · Accession: 0001654954-23-015475

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-275931

Date

December 15, 2023

Author

Form

CORRESP

Company

Dermata Therapeutics, Inc.

Letter

VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Requested Date: December 15, 2023 Requested Time: 4:30 p.m., Eastern Time

Re:

Dear Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Dermata Therapeutics, Inc. (the “Company”) hereby requests that the above-referenced Registration Statement (the “Registration Statement”) be declared effective by the Securities and Exchange Commission (the “Commission”) at the “Requested Date” and “Requested Time” set forth above or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Commission.

Please call Tracy Buffer of Lowenstein Sandler LLP at (973) 597-2434 to confirm the effectiveness of the Registration Statement or with any questions.

Sincerely,
DERMATA THERAPEUTICS, INC.

Show Raw Text

CORRESP
1
filename1.htm

drma_corresp.htmDecember 13, 2023

 VIA EDGAR

 United States Securities and Exchange Commission

 Division of Corporation Finance

 Mail Stop 4720

 100 F Street, N.E.

 Washington, D.C. 20549

    Re:

   Dermata Therapeutics, Inc.

   Registration Statement on Form S-3

   File No. 333-275931

   Acceleration Request

   Requested Date:

   December 15, 2023

   Requested Time:

   4:30 p.m., Eastern Time

 Dear Ladies and Gentlemen:

 Pursuant to Rule 461 under the Securities Act of 1933, as amended, Dermata Therapeutics, Inc. (the “Company”) hereby requests that the above-referenced Registration Statement (the “Registration Statement”) be declared effective by the Securities and Exchange Commission (the “Commission”) at the “Requested Date” and “Requested Time” set forth above or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Commission.

 Please call Tracy Buffer of Lowenstein Sandler LLP at (973) 597-2434 to confirm the effectiveness of the Registration Statement or with any questions.

      Sincerely,

     DERMATA THERAPEUTICS, INC.

   By:

   /s/ Gerald T. Proehl

   Name:

   Gerald T. Proehl

   Title:

   Chief Executive Officer

SecProbe.io